Objective consensus from decision trees by unknown
Putora et al. Radiation Oncology 2014, 9:270
http://www.ro-journal.com/content/9/1/270METHODOLOGY Open AccessObjective consensus from decision trees
Paul Martin Putora1*, Cedric M Panje1, Alexandros Papachristofilou2, Alan Dal Pra3, Thomas Hundsberger4
and Ludwig Plasswilm1Abstract
Background: Consensus-based approaches provide an alternative to evidence-based decision making, especially
in situations where high-level evidence is limited. Our aim was to demonstrate a novel source of information,
objective consensus based on recommendations in decision tree format from multiple sources.
Methods: Based on nine sample recommendations in decision tree format a representative analysis was performed.
The most common (mode) recommendations for each eventuality (each permutation of parameters) were
determined. The same procedure was applied to real clinical recommendations for primary radiotherapy for
prostate cancer. Data was collected from 16 radiation oncology centres, converted into decision tree format and
analyzed in order to determine the objective consensus.
Results: Based on information from multiple sources in decision tree format, treatment recommendations can
be assessed for every parameter combination. An objective consensus can be determined by means of mode
recommendations without compromise or confrontation among the parties. In the clinical example involving
prostate cancer therapy, three parameters were used with two cut-off values each (Gleason score, PSA, T-stage)
resulting in a total of 27 possible combinations per decision tree. Despite significant variations among the
recommendations, a mode recommendation could be found for specific combinations of parameters.
Conclusion: Recommendations represented as decision trees can serve as a basis for objective consensus among
multiple parties.
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Many clinical decisions in medicine are based on formal
and informal consensus agreements and recommenda-
tions [1], especially when the level of evidence is not suffi-
cient [2]. For example, due to the lack of clinical studies
many drugs used in adult medicine are not licenced for
children, but may be applied in clinical routine [3]. Like-
wise a growing number of treatable orphan diseases, de-
fined by their low incidence [4,5] and distinct molecular
aberrations in carcinomas [6] may never be amenable to
large phase III studies. The trend towards personalized
medicine and limited resources is forcing us to find solu-
tions which do not exclusively rely on classical levels of
evidence as presented by Sackett et al. [7]. Even where evi-
dence is available, this does not always translate into
evidence-based practice due to lack of competency and is* Correspondence: paul.putora@kssg.ch
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unless otherwise stated.difficult to measure [8]. Consensus methodologies may as-
sist us in acquiring information beyond these gaps.
Several consensus methods exist, including the Delphi
process, the nominal group technique and the consensus
development conference [1,9]. All of these modalities
rely on discussion, negotiation, moderation and human
judgement and are therefore subjective. In certain areas
of medicine consensus meetings have been established
as a pragmatic approach to provide guidance where evi-
dence is not available [10-13]. In addition to “evidence-
based” and “eminence-based” medicine [14], swarm-based
medicine may provide guidance by extracting knowledge
from the behaviour of the medical community [2]. “Crowd
wisdom” can be applied in single numerical estimates as
well as for combinatorial problems [15].
Learning from information of simple structure is easy.
When all parties provide a numeric value a consensus can
be based on simple mathematical operands like mean, me-
dian or the most common value (mode). As the structureLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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When decisions are based on patient and disease charac-
teristics such as three different age groups (e.g. <19, 19–
64, >64 years), gender (male, female) and four different
histologic types (e.g. in lung cancer: adenocarcinoma,
squamous cell carcinoma, small cell or “not otherwise
specified”) a total of 24 eventualities arise (3 × 2 × 4).
By adding further criteria the number of possible com-
binations rises exponentially.
Multiple decision criteria can be integrated in a guide-
line with the help of decision trees, such as the clinical
practice guidelines of the National Comprehensive Cancer
Network [16].
This study aims to demonstrate how standardised
elements (diagnostic nodes) [17], can be implemented
to analyse and compare multiple recommendations from
various parties in order to provide an account of unbiased
consensus.
Methods
Decision trees can serve in decision support and are
tree-like representations of decisions and their conse-
quences. By connecting several elements from a start-
ing point a decision tree can be constructed by adding
possible options as branches. Recommendations (or
actions) are situated at the end of the branches (analo-
gous to leaves at the end of each branch). Nodes repre-
senting predefined parameters (diagnostic nodes [17])
were used to construct clinical decision trees. For exam-
ple, the parameter gender is represented by two nodes (orFigure 1 Nine sample decision trees are named “A” to “I”. Each tree st
and their values it is possible to follow each decision tree from left to right
are “Nothing”, “Drug A”, “Radiotherapy” and “Operation” in these examples.branches): “male” or “female” and age e.g. by “<65 years”
or “>65 years”. For later cross-comparison unified categor-
ies are important; should, for example, age be classified by
one party by years (<19 years, 19 – 64 years, >64 years)
and another party by category (age = old, age = young),
an automated evaluation and comparison would be not
possible.
For exploration, simple random criteria were defined
(e.g. age, visibility, histology) to include different data
types and ranges, i.e. numeric values with a range (age:
0–140 years), Boolean (visibility: true/false) or catego-
rical (histology: benign/malignant). These parameters
were randomly combined to create nine different deci-
sion trees of varying complexity [17] (Figure 1). To pro-
vide altering treatment recommendations “radiotherapy”,
“operation”, “DrugA” and “nothing” were randomly as-
signed to the decision tree branches.
For any given combination of parameters each tree
can be traced from the starting node (left side in the
figures) to the final recommendation (leaf ). Even if no
common parameters are used, any combination of pa-
rameters can be tested. For example when the situation
“Visible = Yes, BMI < 25 and Histology = malignant” is
used (Figures 1 and 2), tree “A” recommends “Opera-
tion” and tree “B” “Radiotherapy”. As tree “A” does not
implement the parameter “Histology”, this is ignored
and the recommendation is based on the other two
parameters: “Operation”. In tree “B”, only the param-
eter “Histology = malignant” is relevant, resulting in
“Radiotherapy”.arts at the root on the left side of the tree. Based on the parameters
to reach a specific treatment recommendation. The recommendations
Figure 2 The result of a direct comparison of two decision trees is displayed. The resulting tree has a more complex structure than the
input trees. When decision trees “A” and “B” are compared, the parameters can be followed from the left to the right to reach specific
recommendations for every combination from each party. In the second combination of parameters seen from the top of the graph, party A
would recommend an “Operation” whereas party B would recommend “Radiotherapy”. In the bottom row, both parties would
recommend “Radiotherapy”.
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can be evaluated by considering every possible param-
eter combination of every decision tree.
To provide a clinical example, we collected and anon-
ymized treatment recommendations on prostate cancer
from 16 radiation oncology centres. The prescribed do-
ses for radiotherapy depending on the T-stage, Gleason
Score and PSA were collected. Additionally, we collected
the criteria for starting androgen deprivation therapy as
well as its duration. Only recommendations outside of
clinical trials were considered; details on radiotherapy
treatment such as margins, patient setup were not con-
sidered for this example. Obtaining the decision trees
from individuals in various centres consisted of a first
query on the general treatment strategy for prostate
cancer. These were then specified in brief discussions
(mostly per email) and converted into decision trees by
PMP and CP. The decision trees were provided to the
participating individuals for correction and approval.
As the parameters used were identical among centres,
the recommendations were converted into a decision
tree format using these same parameters.
The decision trees were then analysed to determine
the most common recommendations for each possible
combination of parameters, based on this, the most com-
mon (mode) recommendation could be determined.
The analysis was performed semi-automatically with a
web-based software specifically designed for this task.The software was developed in Java programming lan-
guage using a BigTable database and ran on the Google
Cloud Platform AppEngine. Input was provided manu-
ally through a website interface which was built using
Google Web Toolkit Framework. For the visualisation of
decision trees a free JavaScript library called JIT InfoVis
has been used. In order to provide comparison results
for many and big decision trees in reasonable time the
calculation was parallelised and executed on multiple
machines within the Google Cloud Platform. For this
purpose a mechanism called Task Queue and Google
Pipeline application programming interface (API) was
used.
Ethics and consent
The presented research did not involve human subjects,
material or data.
Results
By a direct comparison of two decision trees the pa-
rameters of both are implemented in the result. The
combination of decision trees “A” and “B” from Figure 1
results in a more complex structure (Figure 2). Even
though decision trees A and B are easily understood by
themselves, the complexity of their comparison is less
intuitive. The resulting comparison of recommenda-
tions of all nine decision trees from Figure 1 is shown
in Figure 3.
Figure 3 A partial view of the direct comparison of nine decision trees. The recommendations of multiple parties are displayed in one tree.
In the configuration of parameters on the top of the combined decision tree, all parties except for “H”, “G” and “C” would recommend the
treatment option “Operation”.
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tions can be used as a basis for determining the most
common (mode) recommendation for each eventuality
separately. These can be used to construct a mode
decision tree. In the provided example, consensus was
considered to be available if any recommendation was
provided as the most common. When two recommen-
dations were equally represented (e.g. three centres “Drug
A”, three centres “Radiotherapy”), this was considered no
consensus. Where consensus was established, the per-
centage of congruence was also determined. Figure 4
shows the resulting mode decision tree of nine sample
decision trees.
In our clinical example of 16 radiation oncology de-
partments all centres used the same cut-off values for
Gleason score, PSA and T-Stage, each divided into three
risk groups. This resulted in a maximum of 27 permuta-
tions. Based on a direct comparison between these algo-
rithms, all recommendations for the subset of prostate
cancer with T stage up to T2a, PSA under 10 ng/ml and
a Gleason of 7 are represented (Figure 5).
When the direct comparison of the trees was analysed,
it was possible to determine whether a mode recommen-
dation was present, and how frequent this was. Figure 6
shows a section of the mode-decision tree, this is derived
from an analysis of the full comparison, it is represented
by a subset mode recommendation shown in Figure 5.
Discussion
In order to determine the level of consensus among
multiple parties, the individual positions of each party
need to be available. In order to provide an objectivebasis for analysis, a collection of these recommendations
in compatible format is required. The ideal format is a
complete decision tree representing every possible com-
bination of relevant parameters. However, this is often
not readily available. Alternatively a short free-text
version can be provided, the essence of which can be
transformed into a decision tree. This decision-tree can
then be iteratively checked against clinical scenarios and
every possible combination of parameters. The parameters
need to be clearly defined and agreed upon by all partici-
pating parties.
Of note, the implementation of each parameter within
a recommendation tree is not mandatory. For instance,
the parameter “histology” is not included in tree A but is
implemented in others (Figure 1). In clinical routine not
every parameter is used by all parties. Due to the inherent
structure of a decision tree, the order of the parameters is
not relevant as long as the parameter combinations lead
to the same recommendation.
The mode decision tree is a transparent method to de-
termine the agreement of multiple recommendations of
varying structure within the same clinical context based
on objective and standardized interpretation.
Areas of controversy and consensus can be equally rep-
resented. The completeness of the mode decision tree can
provide users with guidance where traditional consensus
methodologies or statements remain inconclusive.
Depending on the context, the anonymity of parties
within a consensus effort may be of great value. Analysis
of anonymously provided input can exclude any bias to-
wards more influential parties and avoids direct confron-
tation among parties.
Figure 5 Recommendations from 16 centres on prostate cancer radiotherapy and androgen deprivation therapy are represented here.
The treatment consists of the prescribed total biologically equivalent dose of RT to the prostate and the duration represents the duration of
recommended ADT. Here all recommendations for T stage T1-T2a, PSA < 10 ng/ml and Gleason 7 are represented.
Figure 4 The mode consensus for 9 input trees is displayed. All criteria relevant for recommendations are displayed and any parameter
combination followed to reach the recommendations on the right. For the top row, when the appropriate criteria are fulfilled the most common
recommendation (consensus) was “Operation” for six out of nine recommendation trees (6/9). In the second row, a consensus could not be
established (no single dominant mode recommendation for this specific subset).
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Figure 6 The consensus tree demonstrates that there is very little consensus in this scenario. In the scenario with “Gleason = 7” a
“consensus” is represented as the most common recommendation. For different Gleason score values no single most common recommendation
could be found.
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per party increases with the number of parties [1,9],
while with the mode-decision tree approach the effort
per party is constant irrespective of the total number of
participants.
Difficulty in implementing this methodology may re-
sult from the effort required to produce a recommenda-
tion tree covering all eventualities. Parties are faced with
the problem of externalising intrinsic knowledge and
every-day know-how in the form of a decision tree [18].
In clinical practice, selected permutations (eventualities)
may be very rare and physicians may never have to decide
on certain issues. For example, the choice of chemother-
apy for lung cancer in a 55-year old pregnant woman with
renal insufficiency may never be needed. When recom-
mendations are collected in decision tree format, the users
must either provide a recommendation for these situa-
tions (as all permutations should be covered) or actively
decide that they cannot. Interdependent hierarchical pa-
rameters are not suitable for automated decision tree
comparison with this method. For example, should a
decision tree include the recommendation “operation”
and then further recommendations based on how this
treatment worked “follow-up” after “gross total resection”
or “adjuvant radiotherapy” after “subtotal resection” in-
consistencies would arise. The latter recommendations
are exclusive to their higher level criteria and not applic-
able without this condition. Depending on the complexity
a potential approach might be to define one decision tree
up to the recommendation (e.g. “operation”) and another
one with this recommendation as a starting point.
An interesting option is party reselection: creating
a mode decision tree from a subgroup (e.g. analysing
the input from all participants of a single country). Forindividual questions, weighting may be based on prop-
erties of the parties (e.g. the number of patients treated
per party). For example should all users within a set
provide their recommendation trees and the number of
patients treated, an estimate of how the majority of
patients are treated can be made.
Digital communication may not replace direct contact
where required, but may help determine various issues
before any face-to-face meeting. Dynamic interpretation
of up-to-date input allows for an automatic update; the
mode decision tree can be instantly re-evaluated from
current data.
A limitation of this approach is that its advantages be-
come apparent only at a certain complexity range. Should
the issue under evaluation involve e.g. two parameters and
few users, a simple table would provide adequate visuali-
sation. In the other extreme, should the context require
many complex parameters the number of permutations
may exceed millions. The methodology remains applic-
able, but the result may be too complex for practical inter-
pretation. Feasibility is dependent on the question being
asked, should the question involve the search for specific
parameter combinations with complete consensus or a
specific recommendation – the number of parameters
may be higher and still result in a usable product (when
filtered for complete consensus for example). Independent
of the number of parameters, the system could be used to
find the most common recommendation for a specific
parameter combination. Typically, to provide feasible out-
put for all parameter combinations the number of param-
eters should be kept in single digits.
Due to the accepted cancer classification (i.e. TNM-
staging system), oncological diseases are very suitable to
automated classifications. As demonstrated in the clinical
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is possible to determine the specific recommendation
from each party based on the decision trees (e.g. for
a cT2b Gleason 8 prostate cancer with a PSA value
of 15.2 ng/ml). The most common recommendation
for such a patient can be determined from the mode
decision tree. Besides having criteria multiple parties
agree upon (e.g. the TNM staging system) it is import-
ant to have explicit and complete local standards in
place to make any automated comparison feasible in
routine practice. The authors are currently involved in
projects testing this method in several clinical scenarios
with various partners. Once a system of criteria is set
up for a specific clinical problem and tested, adding
further individuals/centres is associated with relatively
little effort, such an approach may form the basis for
possible routine clinical implementation. The results
of the decision tree analysis, for example the mode
decision tree may readily serve as a clinical decision
making tool.
If the decision criteria implemented are identical to
the criteria used in published guidelines an automated
comparison of an individual tree or the mode decision
tree to these guidelines would be possible. If this is the
aim, parameters should be prospectively defined as it is
possible that further criteria might be used in individual
trees not considered in published guidelines.
The mode consensus does not provide any reasoning
or justifications and should be interpreted for what it
is – an objective analysis of the information provided
by participants.
Conclusions
Diagnostic nodes can be used as a basis for a consensus-
finding process from different recommendations within
the same clinical context. The mode decision tree me-
thodology may provide a useful instrument to enhance
existing methodologies in consensus finding and is not
limited to specific areas of clinical medicine. We could
demonstrate the applicability on an abstract as well as a
specific clinical example. As the mode decision trees
represent an objective consensus based on current input,
it may provide a valuable source of guidance on a case-
by-case basis and thus be implemented in daily routine.
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